Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.

× No keyword cloud information.

10 in total

Review 1. Targeting CCR5 for anti-HIV research.

Authors: W-G Gu; X-Q Chen
Journal: Eur J Clin Microbiol Infect Dis Date: 2014-06-11 Impact factor: 3.267

2. Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5.

Authors: Ya Zhu; Yan-Long Zhao; Jian Li; Hong Liu; Qiang Zhao; Bei-Li Wu; Zhen-Lin Yang
Journal: Acta Pharmacol Sin Date: 2018-06-25 Impact factor: 6.150

3. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Authors: Olga Latinovic; Marvin Reitz; Nhut M Le; James S Foulke; Gerd Fätkenheuer; Clara Lehmann; Robert R Redfield; Alonso Heredia
Journal: Virology Date: 2011-01-12 Impact factor: 3.616

4. Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

Authors: Olga Latinovic; Nhut Le; Marvin Reitz; Ranajit Pal; Anthony DeVico; James S Foulke; Robert R Redfield; Alonso Heredia
Journal: AIDS Date: 2011-06-01 Impact factor: 4.177

5. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors: Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal: Proc Natl Acad Sci U S A Date: 2008-12-15 Impact factor: 11.205

6. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.

Authors: Qiuxiang Tan; Ya Zhu; Jian Li; Zhuxi Chen; Gye Won Han; Irina Kufareva; Tingting Li; Limin Ma; Gustavo Fenalti; Jing Li; Wenru Zhang; Xin Xie; Huaiyu Yang; Hualiang Jiang; Vadim Cherezov; Hong Liu; Raymond C Stevens; Qiang Zhao; Beili Wu
Journal: Science Date: 2013-09-12 Impact factor: 47.728

7. Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.

Authors: Christian Berg; Katja Spiess; Hans R Lüttichau; Mette M Rosenkilde
Journal: Pharmacol Res Perspect Date: 2016-10-18

8. CCR5 Inhibitors and HIV-1 Infection.

Authors: Olga S Latinovic; Marvin Reitz; Alonso Heredia
Journal: J AIDS HIV Treat Date: 2019

9. Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.

Authors: Jianping Sun; Liying Ma; Xiaoling Yu; Yang Huang; Lin Yuan; Yiming Shao
Journal: Virol J Date: 2009-11-18 Impact factor: 4.099

10. The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.

Authors: Qingwen Jin; Hong Chen; Xingxia Wang; Liandong Zhao; Qingchen Xu; Huijuan Wang; Guanyu Li; Xiaofan Yang; Hongming Ma; Haoquan Wu; Xiaohui Ji
Journal: PLoS One Date: 2015-07-08 Impact factor: 3.240

10 in total